Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): A systematic review and meta-analysis

Clinical Rheumatology

Volumn 33, Issue 2, 2014, Pages 165-173

  Zhang, Xingming ^a   Liang, Fuxiang ^a   Yin, Xiaoxue ^a   Xiao, Xiaojuan ^b   Shi, Peiyu ^a   Wei, Dang ^a   Yao, Liang ^a   Wang, Qi ^a   Chen, Yaolong ^a  

^a LANZHOU UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Rheumatoid treatment outcome meta analysis; Tofacitinib arthritis

Indexed keywords

ACUTE DISEASE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MALE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84893936361     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2452-7     Document Type: Review

References (23)

1. U.S. Food and Drug Administration (FDA). Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm. Accessed 1 Aug 2013
2. American College of Rheumatology. Available at: http://www.rheumatology. org/Publications/Hotline/Tofacitinib-for-the-Treatment-of-Rheumatoid-Arthritis/. Accessed 1 Aug 2013
3. Julian PT Higgins, Sally Green (2011) Cochrane handbook for systematic reviews of interventions (version 5.1.0)
4. Higgins JPT AD, Sterne JAC (eds) (2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
5. Schünemann HJ OA, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH (2011) Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
6. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 9865:451-460. doi: 10.1016/S0140-6736(12)61424-X
7. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song Y-W, Tegzova D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, Investigators OS (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559-570
8. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 6:508-519. doi: 10.1056/NEJMoa1112072
9. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 4:970-981. doi: 10.1002/art.33419
10. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/ NCT00856544?term=NCT00856544&rank=1. Accessed 1 Aug 2013
11. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 8:1150-1158. doi: 10.1002/acr.20494
12. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 7:1895-1905
13. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/ NCT00687193?term=NCT00687193&rank=1. Accessed 1 Aug 2013
14. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 3:617-629. doi: 10.1002/art.33383
15. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 6:495-507. doi: 10.1056/NEJMoa1109071
16. Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH (2010) Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2:413-416. doi: 10.1136/ard.2009.108159
17. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/show/ NCT01164579. Accessed 1 Aug 2013
18. WHO International Clinical Trial Registration Platform (ICTRP). Available at: http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2009-016987-34-PL. Accessed 1 Aug 2013
19. WHO International Clinical Trial Registration Platform (ICTRP). Available at: http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2010-020890-18-CZ. Accessed 1 Aug 2013
20. U.S. Food and Drug Administration (FDA). Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisAdvisoryCommittee/UCM304199.pdf. Accessed 1 Aug 2013
21. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631-637. doi: 10.1136/ard.2009.123919
22. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975. doi: 10.1136/ard.2009.126532
23. Ahadieh S, Checchio T, Tensfeldt T, French J, Krishnaswami S, Riese R, Menon S, Boy MG, Geier JL (2012) Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. Arthritis Rheum 64:S726